Pharmafile Logo

News and Press Releases

CWOW 2026: Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

26 March 2026 -- Cambridge, UK -- Cambridge Wide Open Week (CWOW) returns 11–19 June 2026, sharing the spirit and buzz of the week-long,interactive festival with Oxford and London for...

Category: Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2026

o2h
info@o2h.com
Mill SciTech Park, Mill Lane Hauxton, Cambridge CB22 5HX

SLAS Announces the Cohort for Innovation AveNEW at SLAS Europe 2026

Twelve emerging life science startups to showcase enabling technologies at the SLAS European Conference and Exhibition in Vienna, 19-21 May 2026 23 March 2026 -- Vienna, Austria -- SLAS, the...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 23, 2026

Society for Laboratory Automation and Screening
slas@slas.org
1301 West 22nd Street, Suite 708 Oak Brook, IL 60523 USA

BIO-Europe Spring 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon

16 March 2026 -- Munich, Germany -- The global biopharmaceutical community is preparing to gather in Lisbon, Portugal, for the 20th edition of BIO-Europe Spring, the premier springtime partnering conference...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 16, 2026

Informa
media@informa.com
5 Howick Place London SW1P 1WG UK

OBN Invites Life Science Leaders to Celebrate 20 Years of BioTrinity

Featuring keynotes from: Steve Bates, Executive Chair at the Office for Life Sciences, Lawrence Tallon, CEO at the MHRA & Maria Koufali, Life Sciences Industry Director at the NIHR, click...

Category: Other, Pharmaceutical
Posted: March 3, 2026

OBN
info@obn.org.uk
Unit 6 Library Avenue, Harwell, Didcot, OX11 0SG, UK

BIO-Europe Spring 2026 Charts the Future of Life Sciences from Lisbon’s Shores

25 February 2026 -- Munich, Germany -- The 20th annual BIO-Europe Spring is heading to Lisbon, Portugal, from March 23–25, 2026, with a digital experience to follow on March 31–April...

Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: February 25, 2026

Informa
media@informa.com
5 Howick Place London SW1P 1WG UK

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia

Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant schizophrenia (TRS) By targeting the hippocampus region of the brain, evenamide...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 3, 2026

Newron Pharmaceuticals
info@newron.com
via Antonio Meucci 3 20091 Bresso (Mi) Italy

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis 

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan (HRCT) imaging biomarkers as a co-primary endpoint 20 January...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 20, 2026

Brainomix
investors@brainomix.com
First Floor, Seacourt Tower West Way Oxford OX2 0JJ

Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT

20 January 2026 -- Heidelberg, Germany -- Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m)...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 20, 2026

Exciva
info@exciva.com
Hauptstrasse 25, 69117 Heidelberg, Germany

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Issued and pending claims expected to protect ALTO-207 into the mid-2040s 14 January 2026 -- California, US -- Alto Neuroscience, Inc, a clinical-stage biopharmaceutical company focused on the development of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026

Alto Neuroscience
info@altoneuroscience.com
650 Castro Street, Suite 450 Mountain View, CA 94041

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

New patent based on treatment of populations identified to be particularly responsive to ondansetron treatment after examination of Adial’s clinical data and information 14 January 2026 -- Virginia, US --...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron’s global ENIGMA-TRS Phase III development program, enrolling...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 6, 2026

Newron Pharmaceuticals
info@newron.com
via Antonio Meucci 3 20091 Bresso (Mi) Italy

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis

5 January 2026 -- California and Massachusetts, US -- MapLight Therapeutics, Inc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 5, 2026

MapLight Therapeutics
info@maplightrx.com
800 Chesapeake Drive, Redwood City, California 9406

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design Phase 3 initiation targeted...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 5, 2026

GH Research
info@ghres.com
Joshua Dawson House Dawson Street Dublin 2, D02 RY95 Ireland

New collaborative strategy platform launches to empower biopharma teams to reach peak sales faster and with greater confidence

11 November 2025 -- London, UK -- In a drug development landscape defined by shifting policies, geopolitical uncertainty, and increasing competitive pressure, a new collaborative strategy platform, Nmblr, has launched to empower...

Category: Biotechnology, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: November 11, 2025

Nmblr

Five Leading Life Science Organisations Collaborate on Inaugural London Bio-Innovation Week

ELRIG, Life Science Integrates, Life Science Nation, One Nucleus and SLAS will provide delegates with the opportunity for cross-event partnering during London Bio-Innovation week, which runs 1st-5th December, 2025 One...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025

London Bio-Innovation Week
info@onenucleus.com